Beta
158463

EFFECT OF MITOMYCIN C VERSUS BEVACIZUMAB ON CORNEAL ENDOTHELIAL CELLS FOLLOWING TRABECULECTOMY IN PRIMARY OPEN ANGLE GLAUCOMA

Article

Last updated: 24 Dec 2024

Subjects

-

Tags

Surgery

Abstract

Background: Trabeculectomy is the standard treatment for patients with primary open angle glaucoma who had failed maximal tolerated medical therapy. The use of Mitomycin C (MMC) or Bevacizumab as adjuvant during trabeculectomy reduces fibrosis which in turn increases the possibility of success in filtrating surgery. However, MMC or Bevacizumab can lead to adverse effects, such as corneal toxicity especially on corneal endothelium, hypotony, formation of avascular cystic blebs, leaks, blebitis, and endophthalmitis.
Objective: To evaluate and compare corneal endothelial cell changes before and after trabeculectomy with subconjunctival Mitomycin C versus trabeculectomy with sub conjunctival Bevacizumab in primary open angle glaucoma patients (1 month and 6 months postoperatively).
Patients and methods: In this study, 20 patients (with 20 eyes) were divided into two equal groups: (Group A) included patients who underwent subscleral trabeculectomy with adjuvant intraoperative use of 0.2mg/ml MMC for 2 min, and (Group B) included patients who underwent subscleral trabeculectomy with subconjunctival injection of 1.25 mg/0.1 ml Bevacizumab.
     Non-contact specular microscope (Topcon sp-1p, Topcon Medical Inc., Japan) was done preoperatively, one month postoperatively and six months post-operatively to assess the corneal endothelium as regard ECD (cells/mm²), CV in cell size, HEX and CCT.
     This prospective comparative study was done at Department of ophthalmology, Sayed Galal University Hospital, Cairo, Egypt, and it was carried out from February 1ˢͭ 2019 to October 30ͭ ͪ  2020.
Results: Six males (60%) and four females (40%) in group A while five males (50%) and five females (50%) in group B. The patients' ages ranged from {25 to 47 years} (mean age35.70±6.70) in group A, and ranged from {20 to 45 years} (mean age 31.20±8.70) in group B. MMC and Bevacizumab did not have the same effect on corneal endothelium.
     There was a significant decrease in endothelial cell density (ECD) after six months post-operatively in both groups with significant difference between the two groups, and insignificant increase in central corneal thickness (CCT) after six months post-operatively in both groups, Also there was a significant changes in coefficient of variation (CV), and percentage of hexagonal cells (HEX), an increase in CV (polymegathism), and decrease in hexagonality (pleomorphism) in both groups, with significant difference between the two groups.
Conclusion: MMC affected all parameters of endothelial cells more than Bevacizumab.

DOI

10.21608/amj.2021.158463

Keywords

Bevacizumab, mitomycin c, Specular microscopy (SP), endothelial cell density (ECD), Coefficient of variation (CV), percentage of hexagonal cells (HEX) and central corneal thickness (CCT)

Authors

First Name

Mahmoud

Last Name

Samir Ali El-Rifai

MiddleName

-

Affiliation

Department of Ophthalmology, Faculty of Medicine, Al-Azhar University

Email

mahmoudsamir028@gmail.com

City

-

Orcid

-

First Name

Hassan

Last Name

Mohamed Hegazy

MiddleName

-

Affiliation

Department of Ophthalmology, Faculty of Medicine, Al-Azhar University

Email

-

City

-

Orcid

-

First Name

Mahmoud

Last Name

Hamed Allam

MiddleName

-

Affiliation

Department of Ophthalmology, Faculty of Medicine, Al-Azhar University

Email

-

City

-

Orcid

-

Volume

50

Article Issue

2

Related Issue

23274

Issue Date

2021-04-01

Receive Date

2021-03-22

Publish Date

2021-04-01

Page Start

1,139

Page End

1,152

Print ISSN

1110-0400

Link

https://amj.journals.ekb.eg/article_158463.html

Detail API

https://amj.journals.ekb.eg/service?article_code=158463

Order

31

Type

Original Article

Type Code

941

Publication Type

Journal

Publication Title

Al-Azhar Medical Journal

Publication Link

https://amj.journals.ekb.eg/

MainTitle

EFFECT OF MITOMYCIN C VERSUS BEVACIZUMAB ON CORNEAL ENDOTHELIAL CELLS FOLLOWING TRABECULECTOMY IN PRIMARY OPEN ANGLE GLAUCOMA

Details

Type

Article

Created At

22 Jan 2023